Key result
Catheter-directed tPA resolves thrombosis in ~75% of single-ventricle patients without bleeding complications.
Why the study?
Does catheter-directed recombinant tissue plasminogen activator improve thrombosis resolution in single ventricle patients with aortic root or coronary thrombosis?
Case Report (n=4)
No
Does catheter-directed recombinant tissue plasminogen activator improve thrombosis resolution in single ventricle patients with aortic root or coronary thrombosis?
Catheter-directed tPA is a feasible intervention for aortic root and coronary thrombosis in high-risk single ventricle patients.
Answers are grounded in this paper and cite their sources.
May support feasibility in select single ventricle cases; leaves open need for prospective trials to confirm safety and efficacy.
We present a case series of 4 single ventricle patients with either native aortic root and/or coronary thrombosis who underwent catheter-directed thrombolysis with recombinant tissue plasminogen activator therapy. Two presented after cardiac arrest and extracorporeal membrane oxygenation cannulation, 1 patient with new ventricular dysfunction and ischemic electrocardiogram changes, and 1 presented with recalcitrant systemic vascular resistance crises. Thromboses resolved in 3 of 4 patients. The procedure was well tolerated without complications.
No takes yet. Share an insight, caveat, or question.
Pacella et al. (2026) conducted a case report in Single ventricle with aortic root and/or coronary thrombosis (n=4). Catheter-directed recombinant tissue plasminogen activator was evaluated on Thrombosis resolution. Catheter-directed recombinant tissue plasminogen activator therapy resolved thromboses in 3 of 4 single ventricle patients without bleeding complications.
Synapse has enriched 10 related papers. Consider them for comparative context: